Journal of Neurology

, Volume 254, Supplement 5, pp 13–18

Where do we stand in the treatment of Parkinson's disease?



This article reviews the current situation regarding the treatment of Parkinson's disease (PD). How to apply the various therapeutic options to treat PD appears to be internationally agreed, but the currently available treatment methods are said to be all symptomatic ones. However, some of these may have marginal disease modifying effects. In addition, there are many investigational interventions aiming at modification of the disease processes; some of these interesting strategies are reviewed here. Regarding the currently available drugs, dopamine agonists may delay the loss of dopamine transporters in the striatum and even L-dopa may have some neuroprotective effects. Monoamine oxidase B inhibitors and coenzyme Q10 may also be disease modifying. Recently, a more systemic approach to finding disease modifying drugs has been initiated in the United States which has revealed that creatine and minocycline might have a small disease modifying effect. Although the disease modifying effect of each drug is small, eventually it may be possible to find more potent drugs for PD using this approach. Another important issue is to exchange specialists' “know-how” on the management of various problems arising from long-term L-dopa treatment such as disabling dyskinesia. Although it has not been proven by controlled clinical trials, giving small amounts of liquid L-dopa in frequent doses may be helpful in reducing the severity of dyskinesia and wearing off phenomenon.

Key words

Parkinson's disease treatment neuroprotection guidelines 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  2. 2.
    Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S (2001) Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56:1559–1564PubMedGoogle Scholar
  3. 3.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group (2004) Pramipexole vs L-dopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053PubMedCrossRefGoogle Scholar
  4. 4.
    Innis RB, Marek KL, Sheff K, Zoghbi S, Gastronuovo J, Feigin A, Seibyl JP (1999) Effect of treatment with Ldopa/ carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14:436–442PubMedCrossRefGoogle Scholar
  5. 5.
    NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671CrossRefGoogle Scholar
  6. 6.
    Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, Rinne JQ (2000) Reproducibility and effect of L-dopa on dopamine transporter function measurements: a [F-18]CFT PET study. J Cereb Blood Flow Metab 20:1604–1609PubMedCrossRefGoogle Scholar
  7. 7.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and L-dopa on the progression of Parkinson's disease. Ann Neurol 38:771–777PubMedCrossRefGoogle Scholar
  8. 8.
    Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R; Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 66:1200–1206PubMedCrossRefGoogle Scholar
  9. 9.
    Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364–1371CrossRefGoogle Scholar
  10. 10.
    Parkinson Study Group (1993) Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176–183CrossRefGoogle Scholar
  11. 11.
    Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring L-dopa.Ann Neurol 39:29–36Google Scholar
  12. 12.
    Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring L-dopa. Ann Neurol 39:37–45CrossRefGoogle Scholar
  13. 13.
    Parkinson Study Group (2000) Pramipexole vs L-dopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284: 1931–1938CrossRefGoogle Scholar
  14. 14.
    Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs L-dopa on Parkinson disease progression JAMA 287:1653–1661Google Scholar
  15. 15.
    Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561–566CrossRefGoogle Scholar
  16. 16.
    Parkinson Study Group (2004) L-dopa and the progression of Parkinson's disease. N Engl J Med 351:2498–2508CrossRefGoogle Scholar
  17. 17.
    Rascol O, Brooks DJ, Korczyn AD,De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or L-dopa. New Engl J Med 342:1484–1491PubMedCrossRefGoogle Scholar
  18. 18.
    Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60:1234–1240PubMedGoogle Scholar
  19. 19.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind L-dopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):23–30PubMedCrossRefGoogle Scholar
  20. 20.
    Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550PubMedCrossRefGoogle Scholar
  21. 21.
    Thomas A, Iacono D, Luciano AL, Amellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75:141–143PubMedGoogle Scholar
  22. 22.
    Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl AJ, Watts RL, Brooks DJ (2002) The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 58(Suppl 3):A82–A83Google Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  1. 1.Dept. of Neurology, Research Institute for Diseases of Old AgeJuntendo University School of MedicineTokyoJapan

Personalised recommendations